Open Badges Letter

Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury

Barry Dixon1*, Marcus J Schultz2, Jorrit J Hofstra2, Duncan J Campbell34 and John D Santamaria1

Author Affiliations

1 Department of Intensive Care St. Vincent's Hospital, 41 Victoria Parade, Fitzroy, Melbourne, Victoria, 3065, Australia

2 Department of Intensive Care Medicine & Laboratory of Experimental Intensive Care and Anesthesiology, The Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

3 St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Melbourne, Victoria, 3065

4 Department of Medicine, The University of Melbourne, Clinical Sciences Building, 29 Regent Street, Fitzroy, Melbourne, Victoria, 3065, Australia

For all author emails, please log on.

Critical Care 2010, 14:445  doi:10.1186/cc9269

See related research by Dixon et al.,

Published: 20 October 2010

First paragraph (this article has no abstract)

Previously in this journal, we published a phase 1 study of nebulized heparin in patients with acute lung injury [1]. Patients were administered heparin at doses of 50,000, 100,000, 200,000, or 400,000 U/day for 2 days, and bronchoalveolar lavage (BAL) fluid samples were taken at baseline and after the last heparin dose. The study demonstrated a trend to reduced coagulation activation (prothrombin fragments) in BAL fluid after the last dose of nebulized heparin [1].